1. Group revenue and margin target - ₹250 Cr+ and ≥15% EBITDA by FY27 - Management targets revenue of ₹250 Cr+ and an EBITDA margin of ≥15% by FY27, with FY26 revenue already reaching ₹150.62 Cr and profit before tax rising to ₹10.97 Cr. Hitting that margin target on the guided revenue would lift EBITDA from roughly ₹1.2 Cr to over ₹37 Cr, transforming the earnings base.
2. Brownfield expansion - Unit II capacity addition - A brownfield expansion at Unit II is adding 30% capacity by FY26, with capex on plant and equipment rising to ₹24.90 Cr in FY26 from ₹21.86 Cr in FY25 and a new 20,000 sq. ft. warehouse already built. The expansion relieves a binding constraint - utilisation was \~90% on \~1,000 million units of installed capacity - so the added output flows almost directly to revenue.
3. Complex generics pipeline - oncology, diabetes, cardiovascular - Eight-plus products are in advanced development for the UK, SEA, and Africa, and the CEO points to 4-6 new dossier filings for the UK, Europe, and Australia plus an oncology MR tablet launch. These high-barrier, low-volume products carry richer margins than standard generics, directly supporting the ≥15% EBITDA target.
4. Own-brand launches in emerging markets - The company has launched its own brands in Sri Lanka, Philippines, Tanzania, and Nigeria across diabetes, cardiovascular, and oncology therapies, with active product registrations in over 20 countries and over 200 products pending registration in Africa, Asia, and RoW. Own-brand sales typically earn higher margins than contract manufacturing, so each registration that converts to revenue improves the mix.
5. CRAMS partnerships - contract manufacturing for UK and SEA pharma - Bafna has active contract manufacturing partnerships with British and Southeast Asian pharmaceutical companies and is investing in R&D and tech-transfer capabilities to become a formulation-to-commercial-production partner. Deepening these relationships provides a steady, asset-light revenue stream that raises facility utilisation without the working-capital burden of own-brand launches.
6. ICRA outlook upgrade - Positive on ₹50 Cr bank facilities - ICRA revised the outlook on Bafna’s long-term bank facilities to Positive while reaffirming the [ICRA]BB+ rating on ₹50 Cr of limits. An eventual rating upgrade would lower the cost of debt and signal creditworthiness to overseas buyers and partners, smoothing the path for the export push.